Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)

12 Months Ended

Dec. 31, 2021

Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019 (in thousands, except share and per share amounts):

	Year Ended December 31,
	2021			2020			2019
Net loss attributable to Adaptive Biotechnologies Corporation	$	(207,279	)	$	(146,227	)	$	(68,606	)
Fair value adjustment to redemption value for Series E-1 convertible preferred stock options		—			—			(964	)
Net loss attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(207,279	)	$	(146,227	)	$	(69,570	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		140,354,915			131,216,468			69,165,315
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(1.48	)	$	(1.11	)	$	(1.01	)

Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the years ended December 31, 2021, 2020 and 2019, as they had an anti-dilutive effect:

	Year Ended December 31,
	2021		2020		2019
Convertible preferred stock (on as if converted basis)		—		—		46,104,469
Stock options issued and outstanding		13,097,374		16,125,548		17,183,546
Nonvested restricted stock units		693,173		38,125		4,952
Common stock warrants		8,570		56,875		55,961
Convertible preferred stock warrant		—		—		28,204
Total		13,799,117		16,220,548		63,377,132